In vitro differentiation of ESC-derived hematopoietic precursors to CD4+/CD8+ double-positive T cells. (A) Schematic of early stage T cell development. ESCs derived hematopoietic precursor cells (HPCs; Fig. 2) were cultured on OP9-DL1 cells to provide DL-1 mediated notch signalling that is needed...
more
In vitro differentiation of ESC-derived hematopoietic precursors to CD4+/CD8+ double-positive T cells. (A) Schematic of early stage T cell development. ESCs derived hematopoietic precursor cells (HPCs; Fig. 2) were cultured on OP9-DL1 cells to provide DL-1 mediated notch signalling that is needed to commit differentiation of HPCs to the T cell lineage, including CD4-/CD8- double-negative (DN) early T cell progenitors (DN1), pro-T cells (DN2), which undergo V(D)J recombination to become pre-T cells (DN3), that in turn pass β-selection to develop into DN4 and finally CD4+/CD8+ double-positive (DP) T cells, which express the pan-lymphocyte marker CD3. Absence of the IL2RG gene product leads to an early block in T cell development at DN1 stage (red line). (B) Qualitative assessment of T cell maturation. Differentiation was analysed by flow cytometry after two and four weeks of co-cultivation on OP9-DL1 stroma cells by monitoring surface expression of CD44/CD25 and CD4/CD8 (see also Figure S2). (C,D) Quantitative assessment of T cell maturation. Shown is the average fraction of the various T cell subpopulations with standard error of mean (S.E.M.) of three independent experiments of cells analysed at week 2 (C) or week 4 (D). DN T cell subsets add up to 1.0 at week 2 (C), while at week 4 (D) also CD4 + /CD8 + DP (white columns) and some single-positive cells (not indicated, see Fig. 4) were present. Statistical differences in the fraction of DN1 cells at week 2 are indicated by **(p < 0.01) and ***(p < 0.001). No statistical differences between any of the generated T cell subsets derived from the gene-edited ESC lines and the WT clone was observed at week 4 (p > 0.05). Gating was applied in the following order: FSC/SSC and CD45 + /DAPI- (not shown) to assess CD4/CD8 expression; CD4-/CD8- to gate for DN1-DN4 stages assessed by CD25/CD44 expression. SCID, uncorrected X-SCID ESC clone; C16 and C69, corrected ESC clones; WT, wildtype ESC clone.
less